Les spent seventeen years with Johnson & Johnson Co., Inc., most recently as President of the Dermatological Division of Ortho Pharmaceutical Corporation. Ortho Dermatological was one of the most profitable companies in all of Johnson & Johnson and best known for the Retin-A brand, which ushered in the modern era of aesthetic dermatology. Les was also a member of the Board of Directors of Ortho Pharmaceutical Corporation and the management committees of the corporation – ICOM (International Cilag, Ortho, McNeil) and PRI (Pharmaceutical Research Institute), the worldwide pharmaceutical research function for Johnson & Johnson.
Les left Johnson & Johnson for an opportunity to serve as CEO and President of TriStrata Incorporated and a member of the TriStrata, Inc., and TriStrata Technology, Inc., Boards of Directors. He was a member of the Board of Directors of NeoStrata Company, Inc., a subsidiary of TriStrata, and held the positions of CEO and President. TriStrata and NeoStrata commercialized its patented Alpha hydroxy acid (AHA) inventions on a worldwide basis throughout-licensing and its own sales and marketing efforts. AHAs were the first skincare technology that dermatologists and plastic surgeons promoted in their offices through both retailing home care products and performing in-office lunchtime chemical peels.
Following TriStrata, Les joined Advanced Polymer Systems (APS) as President of Dermatology and Skincare to lead its commercialization and global licensing efforts of its patented topical delivery systems. Cardinal Health acquired APS, and Les then spent two years as President of Cardinal Health, Topical Technologies.
Prior to forming RegimenMD, Les was serving as President & CEO of Riley-Nacht, LLC, a consulting firm he co-founded to develop, license and commercialize skincare technologies. A member of the American Academy of Dermatology, Les has over 30 years of executive experience in the skincare industry in numerous market channels including pharmaceutical, cosmeceutical, OTC, and direct response.Return To Executive Team